DEFENSIN THERAPEUTICS ApS: Financial statements 2017
CVR: 35513280
Source: annual report 2017, Danish Business Authority
01/01/2017 – 31/12/2017
DEFENSIN THERAPEUTICS ApS (CVR 35513280) has filed annual accounts for 2017. In 2017, the company reported a gross profit of DKK 0 and a net result of DKK -2,032,581 compared with DKK 6,028,313 the year before. Equity in the 2017 report amounted to DKK 3,942,399. The solvency ratio was 95.6%.
- Revenue
- DKK 0
- Gross Profit
- DKK 0
- Profit/Loss
- DKK -2,032,581
- Equity
- DKK 3,942,399
- Total Assets
- DKK 4,123,348
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2017 | 0 | 0 | -2 mio. | 3.9 mio. | - |
| 2016 | 11.1 mio. | 11.1 mio. | 6 mio. | 6 mio. | 1 |
| 2015 | - | - | -811 t. | -53 t. | - |
Official annual report
Keep an eye on DEFENSIN THERAPEUTICS ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2017
DEFENSIN THERAPEUTICS ApS has published its annual report for 2016. Revenue came to DKK 11,142,900, and the net result was DKK 6,028,313.
About DEFENSIN THERAPEUTICS ApS
DEFENSIN THERAPEUTICS ApS is a Danish company of the type Anpartsselskab based in København K, founded in 2013. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Peter Hviid Nordkild. The board consists of Ejner Bech Jensen (chair), Matthew Alister Cooper, Peter Hviid Nordkild and Robert Ehehalt. The company's owners include NOVOZYMES A/S, PN INVESTMENT ApS and NEVE INVEST ApS. The company has 0 employees (2018). In 2025, the company reported a gross profit of DKK -538,913 and a net result of DKK -539,063 compared with DKK -130,534 the year before. Equity in the 2025 report amounted to DKK 774,437.